Analysts Raise TransMedics Group, Inc. (TMDX) Price Targets After Q4 Results

Core Insights - TransMedics Group, Inc. (NASDAQ:TMDX) is gaining attention as a promising investment opportunity among hedge funds due to its strong performance and growth potential [1]. Group 1: Analyst Upgrades - Baird raised its price target on TransMedics from $154 to $168 while maintaining an Outperform rating, following the company's Q4 results that exceeded expectations and a positive 2026 outlook [2]. - Oppenheimer increased its price target from $150 to $175 and kept an Outperform rating, highlighting the company's ongoing investments in clinical advancements, particularly in heart and lung, with kidney being the next focus area [3]. - Piper Sandler raised its price target from $140 to $160 and maintained an Overweight rating, noting that the Q4 results surpassed key financial targets and that the revenue guidance for the year appears solid with potential upside [4]. Group 2: Company Overview - TransMedics Group specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, aiming to enhance organ quality preservation, assess viability before transplant, and increase donor organ utilization for treating end-stage heart, lung, and liver failure [5].